Compounds > 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone
Page last updated: 2024-09-03

3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone and Arteriosclerosis

3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone has been researched along with Arteriosclerosis in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Arnesen, H; Falk, E; Kontny, F; Kwong, E; Lyngdorf, L; Meztli, A; Olesen, M; Seljeflot, I1
Burnett, MS; Epstein, SE; Ogunmakinwa, J; Rott, D; Zalles-Ganley, A; Zhou, YF; Zhu, J1
Egan, KM; FitzGerald, GA; Fries, S; Lawson, JA; Lucitt, MB; Puré, E; Wang, M; Zukas, AM1

Other Studies

3 other study(ies) available for 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone and Arteriosclerosis

ArticleYear
No effect of cyclooxygenase inhibition on plaque size in atherosclerosis-prone mice.
    Scandinavian cardiovascular journal : SCJ, 2002, Volume: 36, Issue:6

    Topics: Algorithms; Analysis of Variance; Animals; Aorta, Thoracic; Aortic Diseases; Apolipoproteins E; Arteriosclerosis; Cyclooxygenase Inhibitors; Disease Models, Animal; Furans; Male; Mice; Mice, Inbred C57BL; Sulindac

2002
Effects of MF-tricyclic, a selective cyclooxygenase-2 inhibitor, on atherosclerosis progression and susceptibility to cytomegalovirus replication in apolipoprotein-E knockout mice.
    Journal of the American College of Cardiology, 2003, May-21, Volume: 41, Issue:10

    Topics: Animals; Antibodies, Viral; Apolipoproteins E; Arteriosclerosis; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Cytokines; Cytomegalovirus; Cytomegalovirus Infections; Disease Progression; Disease Susceptibility; DNA, Viral; Dose-Response Relationship, Immunologic; Furans; Immunoglobulin G; Isoenzymes; Mice; Mice, Knockout; Prostaglandin-Endoperoxide Synthases; Viral Load; Virus Replication

2003
Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism.
    Circulation, 2005, Jan-25, Volume: 111, Issue:3

    Topics: Animals; Aorta; Arteriosclerosis; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dietary Fats; Drug Interactions; Furans; Membrane Proteins; Mice; Naphthalenes; Propionates; Prostaglandin-Endoperoxide Synthases; Receptors, Thromboxane; Thromboxane A2

2005